Skip to main content

Efficacy and Safety of Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: A Subgroup Analysis of the Measure Up 1, Measure Up 2, and AD Up Phase 3 Clinical Trials